Specify a stock or a cryptocurrency in the search bar to get a summary
Aslan Pharmaceuticals Ltd ADR
ASLNASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore. Address: 3 Temasek Avenue, Singapore, Singapore, 039190
Analytics
WallStreet Target Price
72 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ASLN
Dividend Analytics ASLN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ASLN
Stock Valuation ASLN
Financials ASLN
Results | 2019 | Dynamics |